Tucson, Arizona / April 17, 2025 — Aspiro Therapeutics, a biopharmaceutical company dedicated to pioneering the development of groundbreaking treatments for obstructive lung diseases, announced today that it has been selected as a Showcase Company at the 2025 Respiratory Innovation Summit (RIS), hosted by the American Thoracic Society (ATS).
Aspiro’s CEO and Co-Founder, James Lovgren, will present on Saturday, May 17 at 2:00 PM PT as part of the RIS program, which runs before the ATS International Conference in San Francisco.
RIS is a premier event connecting scientific innovators, industry leaders, investors, and patient advocates to accelerate the development of transformative respiratory therapies. Aspiro will share its mission to revolutionize care for chronic obstructive pulmonary disease (COPD) and asthma by harnessing the protective power of CC16, a natural lung protein essential to respiratory health.
“We’re honored to be selected as a Showcase Company and to present our vision at RIS,” said James Lovgren. “Aspiro is committed to addressing the underlying mechanisms of obstructive lung diseases, and we look forward to engaging with leaders who share our passion for improving patient outcomes.”
For more information about the Respiratory Innovation Summit, visit LINK
